Discovery: Hormone Mechanism for Weight Loss Uncovered

OU researchers identify brain region targeted by weight-loss hormone FGF21

Apr. 2, 2026 at 6:13am

Got story updates? Submit your updates here. ›

Researchers at the University of Oklahoma have discovered that the hormone FGF21, which reverses obesity in mice, works by signaling to a specific brain region involved in metabolism and appetite regulation. The finding provides valuable insight into the naturally occurring hormone, which is already being examined in clinical trials for treating fatty liver disease.

Why it matters

This research could lead to the development of more targeted and effective weight loss and metabolic disorder treatments without the negative side effects sometimes seen with existing drugs that target similar brain pathways.

The details

The study, published in Cell Reports, found that FGF21 signals to the hindbrain, specifically the nucleus of the solitary tract (NTS) and the area postrema (AP), which then communicate with the parabrachial nucleus to produce the hormone's beneficial metabolic effects. This differs from the GLP-1 drugs, which are believed to act on the hypothalamus to reduce food intake, while FGF21 increases metabolic rate to drive weight loss.

  • The study was published on April 2, 2026.

The players

Matthew Potthoff

The lead author of the study, a professor of biochemistry and physiology in the OU College of Medicine and deputy director of OU Health Harold Hamm Diabetes Center.

University of Oklahoma

The institution where the research was conducted.

Got photos? Submit your photos here. ›

What they’re saying

“In our previous studies, we found that FGF21 signals to the brain instead of the liver, but we didn't know where in the brain. We thought we would find that it signaled to the hypothalamus (which is widely implicated in body weight regulation), so we were very surprised to discover that the signal was to the hindbrain, which is where the GLP-1 analogs are believed to act.”

— Matthew Potthoff, Professor of biochemistry and physiology

“This brain circuit seems to be mediating the effects of FGF21. We hope that by identifying the specific circuit, it can help in the creation of more targeted therapies that are effective without negative side effects. FGF21 analogues have side effects like gastrointestinal issues and, in some cases, bone loss.”

— Matthew Potthoff, Professor of biochemistry and physiology

What’s next

Additional studies are necessary to examine whether the identified brain circuit also mediates the ability of FGF21 and FGF21 analogues to reverse metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease.

The takeaway

This discovery provides valuable insight into the mechanism of action of the weight-loss hormone FGF21, which could lead to the development of more targeted and effective treatments for obesity and related metabolic disorders without the negative side effects sometimes seen with existing drugs.